Abridged Drug Information

**Name of drug:** STAFAL.  
**Composition:** 1 ml of the drug contains Phagi particulae contra staphylococcus polyvalens with $1 \times 10^7$ phage particles at minimum.  
**Therapeutic indications:** STAFAL is intended exclusively for local application in infections caused by staphylococcal strains. It is intended for destruction of staphylococcal cells at the site of ongoing infection.  
**Dosage and route of administration:** The medication should be applied in affected sites, surgical wounds and potential reservoirs by lavage, compressing, spraying, or using a bandage soaked in STAFAL. Intranasal administration: 1-2 drops. Application: twice daily according to clinical symptoms.  
**Contraindications:** Hypersensitivity to any of the components of the drug.  
**Precautions:** Cloudy preparation is unusable. Store at +2 to +8 °C. Protect from light! No drug or other interactions were observed.  
**Use in pregnancy/ lactation:** Consideration should be given by the treating physician to using the drug in pregnancy/lactation. Undesirable effects are not anticipated when applied locally. The drug has no influence on the ability to drive vehicles or operate machinery.  
**Adverse events:** In exceptional cases a burning sensation can develop at the site of application.  
**Packaging:** One packaging contains 1 glass vial of 10 ml.  
**Marketing authorisation holder:** IMUNA Ltd., Průmyslová 1472/11, 102 19 Praha 10, Czech Republic.  
Date of the last revision of the text: September 2012. The drug is available on prescription only. This text does not replace full drug prescribing information. Full drug prescribing information is available upon request.